SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-147270"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-147270" > Phase II trial of z...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004380naa a2200649 4500
001oai:DiVA.org:uu-147270
003SwePub
008110224s2010 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:8dd18488-c38c-4bfc-ac52-6909770d9eda
009oai:prod.swepub.kib.ki.se:121156512
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1472702 URI
0247 a https://doi.org/10.1111/j.1365-2141.2010.08298.x2 DOI
0247 a https://lup.lub.lu.se/record/16739782 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1211565122 URI
040 a (SwePub)uud (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a d'Amore, Francesco4 aut
2451 0a Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
264 c 2010-08-18
264 1b Wiley,c 2010
338 a print2 rdacarrier
520 a The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty-one adult patients with relapsed or refractory CD4+ PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26-85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252 d. Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a peripheral T cell lymphoma
653 a CD4
653 a angioimmunoblastic
653 a anaplastic
653 a zanolimumab
653 a MEDICINE
653 a MEDICIN
653 a angioimmunoblastic
653 a peripheral T cell lymphoma
653 a CD4
653 a zanolimumab
653 a anaplastic
7001 a Radford, John4 aut
7001 a Relander, Thomasu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-tre
7001 a Jerkeman, Matsu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mje
7001 a Tilly, Herve4 aut
7001 a Österborg, Andersu Karolinska Institutet4 aut
7001 a Morschhauser, Franck4 aut
7001 a Gramatzki, Martin4 aut
7001 a Dreyling, Martin4 aut
7001 a Bang, Bo4 aut
7001 a Hagberg, Hansu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)hanshagb
7102 a Bröstcancer-genetikb Sektion I4 org
7730 t British Journal of Haematologyd : Wileyg 150:5, s. 565-573q 150:5<565-573x 0007-1048x 1365-2141
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08298.x
8564 u http://dx.doi.org/10.1111/j.1365-2141.2010.08298.xy FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-147270
8564 8u https://doi.org/10.1111/j.1365-2141.2010.08298.x
8564 8u https://lup.lub.lu.se/record/1673978
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:121156512

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy